Aktuellt
SENASTE
Redeye provides a comment following Magle Group’s announcement of the acquisition of Swedish medtech company Saving Chlora AB. We view the transaction as a modest but strategically aligned move that supports Magle’s ongoing efforts to expand its proprietary pipeline, particularly within advanced wound care. Although the financial scope is limited, the acquisition could enhance Magle’s technology base and product offering, while the deal structure reflects a disciplined approach to capital allocation.
LÄS MER
